Skip to main content
SpringerLink
Log in

Magenkarzinom

  • Chapter
Regionale Therapie maligner Tumoren

  • 1155 Accesses

Zusammenfassung

Das gemeingültige Ziel der Induktionschemotherapie ist traditionsgemäß die Senkung des Risikos einer rezidivierenden Erkrankung mit Fernmetastasen. Die Begründung einer risikoorientierten Vorgehensweise zur definitiven Lokalbehandlung wird zum Zeitpunkt der Diagnosestellung individuell geprüft (und nicht erst nach Beurteilung des Ansprechens auf die Induktionschemotherapie), um ausgewählten Patienten eine unnötige und potentiell toxische begleitende Radiochemotherapie zu ersparen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  1. Taguchi T, Nakamura H, editors. Arterial infusion chemotherapy. Tokyo, Japan: Japanese Journal Cancer and Chemother Publishers Inc; 1994. ISBN 0385–0684.

    Google Scholar 

  2. Shiraha Y et al. Intraarterial infusion of anti-cancer drugs for malignant tumors. Diag Ther (Shindan to Chiryou). 1964;53:43.

    Google Scholar 

  3. Yoshikawa K. Chemotherapy for gastric cancer evaluation of clinical response followed by intraaortic infusion treatment. Jpn J Cancer Clin. 1973;19:776–8.

    Google Scholar 

  4. Taguchi T et al. Arterial infusion chemotherapy for advanced gastrointestinal cancer. Gastroentero Surg (Shoukaki- Geka). 1979;2:1081–8.

    Google Scholar 

  5. Nakano Y et al. Effect of intra-aortic chemotherapy on advanced gastric cancer and colorectal cancers. Jpn J Cancer Chemother. 1978;5:321–7.

    Google Scholar 

  6. Fujita F et al. Chemotherapy for the patients with nonresectable gastric cancer of Bormann type IV. Jpn J Cancer Chemother. 1977;4:1315–22.

    Google Scholar 

  7. Awane Y, Katayanagi T, Kitamura M, et al. Local intra-arterial therapy with adriamycin and 5-FU in progressive cancer. Jpn J Cancer Chemother. 1981;8:1593–9.

    Google Scholar 

  8. Taguchi T et al. Intra-arterial chemotherapy for advanced gastrointestinal cancer. Jpn J Gastroenterol Surg (Shoukaki-Geka). 1974;2:1081–8.

    Google Scholar 

  9. Kitamura M, Awane Y, Katayanagi T, et al. An evaluation of complications associated with continued intra-arterial therapy with carcinostatic drugs. Jpn J Cancer Chemother. 1980;7:1432–8.

    Google Scholar 

  10. Nakajima T et al. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol. 1997;4(3):203–8.

    Article  Google Scholar 

  11. Stephens FO, Adams BG, Grea P. Intra-arterial chemotherapy given preoperatively in the management of carcinoma of the stomach. Surg Gynecol Obstet. 1986; 162:370–4.

    Google Scholar 

  12. Aigner KR, Benthin F, Müller H. Celiac axis infusion (CA1) chemotherapy for advanced gastric cancer. In: Sugarbaker PH, editor. Management of gastric cancer. Boston: Kluwer Academic; 1991. p. 357–62.

    Google Scholar 

  13. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer. 1993;72:37–41.

    Article  PubMed  CAS  Google Scholar 

  14. Glinetius B, Huffmann K, Hoglund U, et al. Initial or delayed chemotherapy with best supportive. Ann Oncol. 1994;5:189–90.

    Google Scholar 

  15. Pyrhonen S, Kuitumen T, Nyandoto P, et al. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus best supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995; 71:587–91.

    Article  PubMed  CAS  Google Scholar 

  16. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma, Fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin and mitomycin. JAMA. 1985; 253(14):2061–7.

    Article  PubMed  CAS  Google Scholar 

  17. Wils JA, Klein HO, Wagener DJ, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of gastric cancer: a trial of European Organization for Research and Treatment of Gastrointestinal Tract Co-operative Group. J Clin Oncol. 1991;9:827–31.

    PubMed  CAS  Google Scholar 

  18. Kelsen D, Atiqu OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin and cisplatin: a randomized trial in gastric cancer. J Clin Oncol. 1992;10:541–8.

    Google Scholar 

  19. Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993;71:3813–8.

    Article  PubMed  CAS  Google Scholar 

  20. Culliman SA, Moertel CG, Wieand HS, et al. Controlled evaluation of three drug combination regimen versus fluorouracil alone in the therapy of advanced gastric cancer. J Clin Oncol. 1994;12:412–6.

    Google Scholar 

  21. Cocconi G, Bella M, Zironi S, et al. Fluorouracil, doxorubicin and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol. 1994;12(12):2687–93.

    PubMed  CAS  Google Scholar 

  22. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997; 15: 261–7.

    Google Scholar 

  23. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.

    Article  PubMed  Google Scholar 

  24. Ohtsu A, Fuse N, Yoshino T, et al. Future perspectives of chemotherapy for advanced gastric cancer. Gastric Cancer. 2009;12:60–6.

    Article  Google Scholar 

  25. Boku N, Yamamoto S, Shirao K, et al. Randomized phase III study of 5-FU alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). J Clin Oncol. 2007;25:LBA 4513.

    Google Scholar 

  26. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9: 215–21.

    Article  PubMed  CAS  Google Scholar 

  27. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegaful plus mitomycin in patients with unresectable advanced gastric cancer: the Japan Clinical Oncology Group Study, (JCOG 9205). J Clin Oncol. 2003;21:54–9.

    Article  Google Scholar 

  28. Imamura H, Iiishi H, Tsuburaya A, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/ TOP002). Gastrointestinal cancers symposium, Orlando; 2008, abstract 5.

    Google Scholar 

  29. Jin M, Lu H, Li J, et al. Randomized three-armed phase III study of S-1 monotherapy versus S-1/CDDP versus 5-FU/ CDDP in patients with advanced gastric cancer SC-101 study. J Clin Oncol. 2008;26:221s (abstract 4533).

    Google Scholar 

  30. Boku N. JCOG trials of systemic chemotherapy for unresectable or recurrent gastric cancer. Gastric Cancer. 2009; 12:43–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Osaka University, 1-18-35-505, Edobori, Nishi-ku, 550-0002, OSAKA, Japan

    Tetsuo Taguchi MD (Emeritus Professor, Chairman of Japan Society for Cancer Chemotherapy)

Authors
  1. Tetsuo Taguchi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medias Klinikum Burghausen, Burghausen

    Karl Reinhard Aigner

  2. University of Sydney, Sydney, Australia

    Frederick O. Stephens

  3. Universitätsklinikum Frankfurt, Frankfurt

    Thomas J. Vogl

  4. Universitätsklinikum Gießen, Gießen

    Winfried Padberg

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Taguchi, T. (2013). Magenkarzinom. In: Aigner, K.R., Stephens, F.O., Vogl, T.J., Padberg, W. (eds) Regionale Therapie maligner Tumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35014-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-35014-6_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-35013-9

  • Online ISBN: 978-3-642-35014-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation